Ziopharm Oncology, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ziopharm Oncology, Inc.
Manufacturers should expect that remote audits of suppliers may take longer than onsite ones until they get more familiar with these audits; it is also important to abide by data confidentiality rules and take frequent breaks when conducting these audits, says Rx-360 CEO.
The new collaboration announced 17 August is worth up to $475m in near-term upfront payments plus undisclosed milestone fees and royalties up to 24%.
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Three separate agreements team the innovative cancer research center with Takeda, Artios/ShangPharma, and Ziopharm. Hoth continues busy deal-making year by licensing gene therapy from North Carolina State.
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Eden Biocell, Ltd